BioLargo, Inc. announced that its patented CupriDyne(R) technology has been proven in a third-party study to be effective in inactivating SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic. The study was conducted by researchers at the Galveston National Laboratory (GNL), a biosafety level (BSL) level 3 lab associated with the University of Texas Medical Branch (UTMB). To introduce a product to market that can make a COVID-19 claim, BioLargo will need approval from the Environmental Protection Agency. It has retained an EPA consultant and is considering the options to fast-track an application, including through a special Section 18 exemption. Management believes that a CupriDyne based COVID-19 product would provide a safe, environmentally friendly spray or misting product to enable effective decontamination of enclosed spaces and public places, and would provide an additional tool for protection to front-line workers and vulnerable persons as governments begin to allow businesses to reopen.